A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in
pediatric participants with pulmonary arterial hypertension. Participants will receive study
treatment for 6 months in the double-blind period (Period 1), and then will be eligible to
enroll into an open-label 2 year extension period (Period 2) during which participants will
receive tadalafil.